StockData

Scynexis vs Spero Therapeutics

SCYX and SPRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SCYX and SPRO compare

Spero Therapeutics is the larger company, worth 1.9 times as much as Scynexis ($55.1M against $29.0M).

Scynexis grew revenue faster over the last twelve months (490% versus −3.3% for Spero Therapeutics).

Spero Therapeutics keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with −53.3% at Scynexis.

Scynexis scores higher on the StockData Score (13 against 11 for Spero Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSCYXSPRO
Size and price
Market cap$29.0M$55.1M
Share price$2.91$0.946
Change, 1 year−38.4%−61.2%
Change, 5 years−95.1%−93.7%
Beta (5Y)1.561.28
Employees1825
StockData Score
Total score13 (better)11
Valuation score33
Growth score2 (better)0
Performance score33
Health score55
Dividend score00
Valuation
P/E–23.7×
P/S1.5×1.2× (better)
P/B0.4× (better)1.2×
EV/EBITDA–0.7×
Fair value$10.10$1.64
Margin of safety71.2% (better)42.4%
Growth
Revenue growth (TTM)490% (better)−3.3%
Revenue growth, 5Y average–48.2%
Profitability
Operating margin−118%12.8% (better)
Net margin−53.3%15.7% (better)
Return on equity−18.4%19.2% (better)
Financial health
Debt / equity0.000.00
Current ratio9.65 (better)6.12
Altman Z-score−5.22 (better)−6.30
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions51.7%36.9%
Held by insiders24.8%24.6%
Insider net buying, 12 months–−$499K
Short interest, % of float6.0%1.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.